Tumor News and Research

RSS

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended a positive opinion for the marketing authorization of XGEVA (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors.

20 May 2011

Curcumin compound can help head and neck cancer cells overcome resistance to chemotherapy drugs

A primary reason that head and neck cancer treatments fail is the tumor cells become resistant to chemotherapy drugs. Now, researchers at the University of Michigan Comprehensive Cancer Center have found that a compound derived from the Indian spice curcumin can help cells overcome that resistance.

20 May 2011

International team identifies key protein in development of drug-resistant leukemia

Now an international team led by researchers at the University of California, San Francisco and joined by scientists of the Freiburg excellence cluster BIOSS - Centre for Biological Signalling Studies, has identified a protein called BCL6 which plays a key role in the development of drug-resistance in leukemia.

20 May 2011

RTOG reports on largest trial for newly diagnosed glioblastoma

RTOG reports on the largest trial to-date for patients with newly diagnosed glioblastoma demonstrating the importance and feasibility of prospective molecular analysis of tumor tissue although finding that patients received no additional benefit from dose-intensive temozolomide as compared to standard adjuvant temozolomide after combined temozolomide and radiotherapy.

20 May 2011

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present preclinical data demonstrating VB-111's potential synergy and additive therapeutic effect when administered in combination with the conventional chemotherapy cancer treatments.

20 May 2011

HealthGrades identifies major flaws in hospital ratings study

The findings of a journal article published in the May issue of the Archives of Surgery are fundamentally flawed and could undermine patients ability to find high quality hospital care, according to HealthGrades. The article, Evaluating Popular Media and Internet-Based Hospital Quality Ratings for Cancer Surgery, compared outcomes for gastrointestinal cancer patients who underwent surgery at hospitals on HealthGrades' "America's 50 Best Hospitals" and US News and World Report's "America's Best Hospitals" lists.

20 May 2011

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

Eli Lilly and Company announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from connective tissues in the body.

20 May 2011

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, in Russia at the State Budgetary Healthcare Institution of Sverdlovsk Region - Sverdlovsk Regional Oncology Center in Ekaterinburg, Russia.

20 May 2011

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for a pivotal Phase 3 clinical trial of ProstAtak™, its lead agent for patients with newly diagnosed prostate cancer.

19 May 2011

Simple lymphocyte count effectively identifies prognosis of renal cell carcinoma

Each year, kidney cancer is diagnosed in nearly 60,000 people in the U.S. Many of these patients undergo surgery to remove the affected kidney, but this procedure can be risky for the elderly and those who have other health problems. Unfortunately, the prognosis of kidney cancer patients often cannot be determined until tumor samples are surgically removed and evaluated.

19 May 2011

Allergy towards electricity after chemotherapy

Janice Tunnicliffe, 55 has become allergic to electromagnetic fields and electricity after a course of chemotherapy for bowel cancer. Fortunately, despite the size of the tumor, her cancer had not spread, but it was decided that she should have chemotherapy after the surgery as a precautionary measure.

19 May 2011

Scientists identify key protein behind drug-resistant leukemia

Acute lymphoblastic leukemia, or ALL, is the most common form of childhood cancer. While most children treated for this disease survive, in a subgroup of patients the disease does not respond to treatment.

19 May 2011

Two genes linked to worst cases of esophageal cancer

University of Rochester Medical Center researchers have pinpointed two genes that are amplified in the worst cases of esophageal cancer, providing data to support a new investigational treatment that targets those same genes.

19 May 2011

New breast cancer biomarker may help identify women's response to tamoxifen

Cancer researchers at the Kimmel Cancer Center at Jefferson and an international team of collaborators have discovered a biomarker in breast cancer that may help identify which women will respond to anti-estrogen therapy.

19 May 2011

Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting

Nektar Therapeutics today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology being held June 3-7, 2011 in Chicago, Illinois.

19 May 2011

Tumor News and Research

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

Curcumin compound can help head and neck cancer cells overcome resistance to chemotherapy drugs

International team identifies key protein in development of drug-resistant leukemia

RTOG reports on largest trial for newly diagnosed glioblastoma

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

HealthGrades identifies major flaws in hospital ratings study

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Simple lymphocyte count effectively identifies prognosis of renal cell carcinoma

Allergy towards electricity after chemotherapy

Scientists identify key protein behind drug-resistant leukemia

Two genes linked to worst cases of esophageal cancer

New breast cancer biomarker may help identify women's response to tamoxifen

Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting

Estradiol may exacerbate tumor growth in breast cancer

'Gatekeeper' protein plays a key role in skin-cancer prevention

Biothera begins dosing in Imprime PGG and cetuximab combination Phase III trial for colorectal cancer

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

Intermittent hypoxia enhances cancer growth in mouse model of obstructive sleep apnea

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News